<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497598</url>
  </required_header>
  <id_info>
    <org_study_id>PUTIM</org_study_id>
    <nct_id>NCT03497598</nct_id>
  </id_info>
  <brief_title>Preventing Recurrent Urinary Tract Infections With α-D-mannose</brief_title>
  <acronym>PUTIM</acronym>
  <official_title>Preventing Recurrent Urinary Tract Infections With α-D-mannose: a Prospective, Randomized, Double-blinded Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Aarau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, women with history of recurrent urinary tract infections (UTIs) will be
      followed over the course of 6 months. The women will be randomized either to D- Mannose or
      Placebo.

      The primary objective of this study is to investigate if treatment with D-mannose reduces the
      risk for a UTI recurrence compared to treatment with Placebo.

      H0: Women with history of recurrent UTIs treated with D-Mannose on average have the same
      number of recurrent UTIs over the course of 6 months compared to women treated with Placebo.

      H1: Women with history of recurrent UTIs treated with D-Mannose on average have fewer
      recurrent UTIs over the course of 6 months compared to women treated with Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of UTIs</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency of UTIs (defined as ≥103 CFU/ 1mL of clean midstream urine) within the 6 months treatment period with D-mannose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>During UTI: Dysuria</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>During UTI: Urgency</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>During UTI: Frequency</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>During UTI: Flank (side) pain</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>During UTI: Cystalgia</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>During UTI: Back pain</measure>
    <time_frame>during every UTI in the 6 months period</time_frame>
    <description>4 categories: no, mild, moderate, severe</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Presence/absence of E. coli, Enterococcus faecali, Klebsiella pneumoniae, Streptococcus agalactiae, Proteus mirabilis, Citro-bacter freundii, Pseudomonas aeruginosa, others not specified</measure>
    <time_frame>at the screening and during every UTI in the 6 months period</time_frame>
    <description>2 categories: yes, no</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>at the screening</time_frame>
    <description>in kilograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>at the screening</time_frame>
    <description>in cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Menopause status</measure>
    <time_frame>at the screening</time_frame>
    <description>3 categories: premenopausal, perimenopausal, postmenopausal</description>
  </other_outcome>
  <other_outcome>
    <measure>Sexual activity</measure>
    <time_frame>at the screening</time_frame>
    <description>2 categories: yes, no</description>
  </other_outcome>
  <other_outcome>
    <measure>Medication</measure>
    <time_frame>at the screening and during every UTI in the 6 months period</time_frame>
    <description>2 categories: yes, no if yes: Name of the medication, dosage, reason for medication, start and end date of medication</description>
  </other_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>at the screening</time_frame>
    <description>in years</description>
  </other_outcome>
  <other_outcome>
    <measure>Birth control</measure>
    <time_frame>at the screening</time_frame>
    <description>2 categories: yes, no</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of CFU</measure>
    <time_frame>at the screening and during every UTI in the 6 months period</time_frame>
    <description>number</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>mannose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
rUTI diary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.
rUTI diary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannose</intervention_name>
    <description>The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.</description>
    <arm_group_label>mannose</arm_group_label>
    <other_name>D-Mannose Oral Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Lactose powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women

          -  ≥ 3 UTIs within the last 12 months or ≥ 2 UTIs within the last 6 months;

          -  Laboratory urine culture: &lt;103 CFUs

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  UTIs ≥ 12 within 1 year

          -  Pregnancy or Lactation

          -  Immune disease

          -  Lactose intolerance

          -  Urinary tract anomaly

          -  Systemic infection

          -  Newly started hormone therapy within the last 6 months

          -  Antibiotic prophylaxis within the last 6 months

          -  α-D-mannose intake within the last month

          -  Use of catheters

          -  Diabetes mellitus

          -  Participation to other studies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Aarau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Ryu, MD</last_name>
    <phone>+41 838 57 38</phone>
    <email>gloria.ryu@ksa.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Ryu, Dr. med</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84. doi: 10.1007/s00345-013-1091-6. Epub 2013 Apr 30.</citation>
    <PMID>23633128</PMID>
  </reference>
  <reference>
    <citation>Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, Benedetti Panici P. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016 Jul;20(13):2920-5.</citation>
    <PMID>27424995</PMID>
  </reference>
  <reference>
    <citation>Phé V, Pakzad M, Haslam C, Gonzales G, Curtis C, Porter B, Chataway J, Panicker JN. Open label feasibility study evaluating D-mannose combined with home-based monitoring of suspected urinary tract infections in patients with multiple sclerosis. Neurourol Urodyn. 2017 Sep;36(7):1770-1775. doi: 10.1002/nau.23173. Epub 2016 Nov 4.</citation>
    <PMID>27813195</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Aarau</investigator_affiliation>
    <investigator_full_name>Gloria Ryu</investigator_full_name>
    <investigator_title>Assistant medical director</investigator_title>
  </responsible_party>
  <keyword>D-mannose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

